New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...

People abused by intimate partners have worse asthma – but researchers are still untangling the reasons behind this surprising link

Uncontrolled inflammation is usually thought to be the culprit behind asthma. But in asthma patients who have survived ...
MedPage Today

Benralizumab Cuts Hypereosinophilic Syndrome Flares

ORLANDO -- Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in ...
Healio

Asthma control improves with tezepelumab, reduced oral corticosteroid use

Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...
TipRanks on MSN

Intellia Therapeutics presents Phase 1/2 data on lonvo-z

Intellia Therapeutics (NTLA) presented positive clinical data from a pooled analysis of all patients who received a 50 milligram dose of lonvo-z ...

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically ...

Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3

RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, ...
Healio

Omalizumab leads biologics in adverse effect risks during asthma treatment

Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...
Jacobs School of Medicine and Biomedical Sciences - University at Buffalo

An In-Depth Look at Asthma, a Mystery Disease of Sorts

The 2025 Lawrence and Nancy Golden Memorial Lectureship on Mind-Body Medicine focused on the psychobiology of asthma.
TMCnet

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a ...

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final ...